

Please type a plus sign (+) inside this box →



File Copy  
Attach to Paper #5

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>	
		Application Number	09/884,875
		Filing Date	June 18, 2001
		First Named Inventor	CHEN, LIN-FENG
		Group Art Unit	4632 1636
Sheet 1 of 3	Attorney Docket Number	UCAL-234	
		Examiner Name	To Be Assigned Leffers

U.S. PATENT DOCUMENTS						
Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	U.S. Patent Documents		Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, columns, lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			
AA2		5,804,374		Baltimore, et al.	09-08-1998	<b>RECEIVED</b>  SEP 11 2002
AA2		6,150,090		Baltimore, et al.	11-21-2000	
AA2		6,410,516		Baltimore, et al.	06-25-2002	

FOREIGN PATENT DOCUMENTS								
Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Foreign Patent Documents			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
			---					

TECH CENTER 1600/2900

OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS			
Examiner Initials <sup>*</sup>	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
AA2		BALDWIN, "The NF- $\kappa$ B and I $\kappa$ B proteins: New discoveries and insights", <i>Annu. Rev. Immunol.</i> (1996) Vol. 14: 649-683.	
		BIRD, "Activation of nuclear transcription factor NF- $\kappa$ B by interleukin-1 is accompanied by casein kinase II-mediated phosphorylation of the p65 subunit", <i>J. Biol. Chem.</i> , (1997) Vol. 272: 32606-32612.	
		BOYES, et al. Regulation of activity of the transcription factor GATA-1 by acetylation", <i>Nature</i> , (1998) Vol. 396: 594-598.	
		CHAKRAVARTI, et al. "A viral mechanism for inhibition of p300 and PCAF acetyltransferase activity", <i>Cell</i> , (1999) Vol. 96: 393-403.	
		CRESS, et al. "Histone deacetylases, transcriptional control, and cancer", <i>J. Cell Physiol.</i> , (2000) Vol. 184: 1-16.	
		DELOUKAS, et al. "Genomic organization of the gene encoding the p65 subunit of NF- $\kappa$ B: Multiple variants of the p65 protein may be generated by alternative splicing", <i>Hum. Mol. Genet.</i> , (1993) Vol. 2: 1895-1900.	
AA2		GERRITSEN, et al. "CREB-binding protein/p300 are transcriptional coactivators of p65", <i>Proc. Natl. Acad. Sci. USA</i> , (1997) Vol. 94: 2927-2932.	

Examiner Signature	<i>Ronald A. Leffers</i>	Date Considered	11/17/02
--------------------	--------------------------	-----------------	----------

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

BEST AVAILABLE COPY



Please type a plus sign (+) inside this box →



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>Substitute for form 1449A/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>	
		<b>Application Number</b>	09/884,875
		<b>Filing Date</b>	June 18, 2001
		<b>First Named Inventor</b>	CHEN, LIN-FENG
		<b>Group Art Unit</b>	1632 1636
<b>Examiner Name</b>	To Be Assigned	SEP 11 2002	
<b>Attorney Docket Number</b>	UCAL-234	TECH CENTER 1600/2900	
<b>Sheet</b>	2	<b>of</b>	3

✓	GHOSH, et al. "NF- $\kappa$ B and rel proteins: Evolutionarily conserved mediators of immune responses", <i>Annu. Rev. Immunol.</i> , (1998) Vol. 16: 225-260.	
✓	HAMAMORI, et al. "Regulation of histone acetyltransferases p300 and PCAF by the bHLH protein twist and adenoviral oncoprotein E1A", <i>Cell</i> , (1999) Vol. 96: 405-413.	
✓	HOTTIGER. "Modulation of cytokine-induced HIV gene expression by competitive binding of transcription factors to the coactivator p300", <i>EMBO J.</i> , (1998) Vol. 17: 3124-3134.	
✓	IMHOF, et al. "Transcription: Gene control by targeted histone acetylation", <i>Curr. Biol.</i> , (1998) Vol. 8: 422-424.	
✓	JACOBS, et al. "Structure of an I-kappa-B-alpha/NF-kappa-B complex", <i>Cell</i> , (1998) Vol. 95(6): 749-758.	
✓	KARIN. How NF- $\kappa$ B is activated: The role of the I- $\kappa$ B kinase (IKK) complex", <i>Oncogene</i> , (1999) Vol. 18: 6867-6874.	
✓	KOUZARIDES. "Acetylation: A regulatory modification to rival phosphorylation?", <i>EMBO J.</i> , (2000) Vol. 19: 1176-1179.	
✓	KRAUS, et al. "Biochemical analysis of distinct activation functions in p300 that enhance transcription initiation with chromatin templates", <i>Mol. Cell. Bio.</i> , (1999) Vol. 19: 8123-8135.	
✓	KUO, et al. "Roles of histone acetyltransferases and deacetylases in gene regulation", <i>Bioessays</i> , (1998) Vol. 20: 615-626.	
✓	LYLE, et al. "An alternatively spliced transcript, p65 delta 2, of the gene encoding the p5 subunit of the transcription factor NF-kappa-B", <i>Gene</i> , (1994) Vol. 138: 265-266.	
✓	MADGE, et al. "A phosphatidylinositol 3-kinase/Akt pathway, activated by tumor necrosis factor or interleukin-1, inhibits apoptosis but does not activate NF-kappa-B in human endothelial cells", <i>J. Biol. Chem.</i> , (2000) Vol. 275: 15458-15465.	
✓	MARTÍNEZ-BALBÁS, et al. "Regulation of E2F1 activity by acetylation", <i>Embo. J.</i> , (2000) Vol. 19: 662-671.	
✓	MAY, et al. "Rel/NF-kappa-B and I-kappa-B proteins: An overview", <i>Sem. Cancer Biol.</i> , (1997) Vol. 8: 63-73.	
✓	MAY, et al. "Signal transduction through NF-kappa-B", <i>Immunol. Today</i> , (1998) Vol. 19(2): 80-88.	
✓	NG, et al. "Histone deacetylases: Silencers for hire", <i>TIBS</i> , (2000) Vol. 25: 121-126.	
✓	PERKINS, et al. "Regulation of NF-kappa-B by cyclin-dependent kinases associated with the p300 coactivator", <i>Science</i> , (1997) Vol. 275: 523-527.	
✓	RUBEN, et al. "Isolation of a rel-related human cDNA that potentially encodes the 65-kD subunit of NF-kappa-B", <i>Science</i> , (1991) Vol. 251: 1490-1493.	

<b>Examiner Signature</b>	<i>Gerald B. Keffeler</i>	<b>Date Considered</b>	11-17-02
---------------------------	---------------------------	------------------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

BEST AVAILABLE COPY



Please type a plus sign (+) inside this box →



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		<b>Complete if Known</b>		<b>RECEIVED</b>
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	09/884,875	
		Filing Date	June 18, 2001	
		First Named Inventor	CHEN, LIN-FENG	
		Group Art Unit	332 1636	
		Examiner Name	To Be Assigned Leffers	
Sheet 3 of 3	Attorney Docket Number	UCAL-234		

SEP 11 2002  
TECH CENTER 1600/2900

PP2	✓	RUNDLETT, et al. "HDA1 and RPD3 are members of distinct yeast histone deacetylase complexes that regulate silencing and transcription", <i>Proc. Natl. Acad. Sci. USA</i> , (1996) Vol. 93: 14503-14508.	
	✓	SEN, et al. "Multiple nuclear factors interact with the immunoglobulin enhancer sequences", <i>Cell</i> , (1986) Vol. 46: 705-716.	
	✓	SAKURAI. "I- $\kappa$ B kinases phosphorylate NF- $\kappa$ B p65 subunit on serine 536 in the transactivation domain", <i>J. Biol. Chem.</i> , (1999) Vol. 274: 30353-30356. D	
	✓	SHEPPARD, et al. "Transcriptional activation by NF- $\kappa$ B requires multiple coactivators", <i>Mol. Cell. Biol.</i> , (1999) Vol. 19: 6367-6378. ✓	
	✓	STERNER, et al. "Acetylation of histones and transcription-related factors", <i>Microbiol. Mol. Biol. Rev.</i> , (2000) Vol. 64: 435-459. ✓	
	✓	SUN, et al. "NF- $\kappa$ B controls expression of inhibitor I- $\kappa$ B $\alpha$ : Evidence for an inducible autoregulatory pathway", <i>Science</i> , (1993) Vol. 259: 1912-1915.	
	✓	TAUNTON, et al. "A mammalian histone deacetylase related to the yeast transcriptional regulator Rpd3p", <i>Science</i> , (1996) Vol. 272: 408-411.	
	✓	WANG. "Tumor necrosis factor $\alpha$ -induced phosphorylation of RelA/p65 on Ser <sup>259</sup> is controlled by casein kinase II", <i>J. Biol. Chem.</i> , (2000) Vol. 275: 32592-32597. D	
	✓	YOSHIDA, et al. "Trichostatin and leptomycin: Inhibition of histone deacetylation and signal-dependent nuclear export", <i>Ann N.Y. Acad. Sci.</i> , (1999) Vol. 886: 23-36.	
PP2	✓	ZHONG, et al. "Phosphorylation of NF- $\kappa$ B p65 by PKA stimulates transcriptional activity by promoting a novel bivalent interaction with the coactivator CBP/p300", <i>Mol. Cell</i> , (1998) Vol. 1: 661-671.	

BEST AVAILABLE COPY

Examiner Signature	<i>Ronald H. Leffers</i>	Date Considered	11/17/02
--------------------	--------------------------	-----------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.